AIM AIM ImmunoTech Inc
Company Analysis
Latest News
🔴 AIM ImmunoTech Inc is trading 5.1% down today as dilution-driven selloff continues
AIM ImmunoTech Inc is trading 5.1% down at $0.39 in pre-market, extending heavy losses following a sharp dilution-driven collapse. • The company recently...
🔴 AIM ImmunoTech Inc is trading 85% down today on heavy dilution from equity issuances used to regain NYSE compliance
AIM ImmunoTech Inc is trading 85% down today at $0.41 as investors react to significant shareholder dilution following recent equity and warrant issuances. •...
AIM ImmunoTech Regains Compliance with NYSE American Listing Standards
AIM ImmunoTech announced it has regained compliance with the NYSE American's continued listing standards after resolving a stockholder equity deficiency. The...
🔴 AIM ImmunoTech Inc is trading 84.27% down today after regaining NYSE American compliance and disclosing new financing
AIM ImmunoTech Inc is trading at $0.43 (-84.27%) after regaining NYSE American compliance with stockholders’ equity requirements. • The exchange removed the...
🟢 AIM ImmunoTech Inc is trading 14.6% up today after regaining NYSE American compliance
AIM ImmunoTech Inc is trading 14.6% up at $0.47 in pre-market sessions. • The company announced today, June 15, 2026, that it has regained compliance with NYSE...
🔴 AIM ImmunoTech Inc makes sharp 11.5% drop
AIM is trading at $0.41, down 11.5% versus the comparison close of $0.46 during regular trading. This is a price-movement alert; no separate company-specific...
🔴 AIM ImmunoTech Inc is trading 85% down today after failing to resolve NYSE American equity-deficiency issues
AIM ImmunoTech Inc is trading 85% down at $0.42 after failing to resolve NYSE American equity-deficiency issues by the June 11, 2026, compliance deadline. •...
AIM ImmunoTech Risks NYSE Delisting, Faces Equity Compliance Deadline
AIM ImmunoTech Inc. faces a June 11, 2026, deadline to regain compliance with NYSE American listing standards. The company must resolve specific deficiencies...
AIM ImmunoTech Announces $1.3 Million Registered Direct Offering and Private Placement
AIM ImmunoTech Inc. entered into a securities purchase agreement with institutional investors for a registered direct offering and a concurrent private...
AIM ImmunoTech Amends Bylaws to Adopt 'Majority of Votes Cast' Voting Standard
AIM ImmunoTech Inc. announced that its Board of Directors approved an amendment to the company's bylaws, effective June 9, 2026, which changes the voting...
AIM ImmunoTech's Fire-Sale Capital Raise Wipes Out 84% of Shareholder Value — Can This Biotech Survive Its Own Desperation?
Shares of AIM ImmunoTech (AIM) cratered 83.7% in a single session, plunging from $2.79 to $0.45, after the company announced a deeply discounted capital raise...
🔴 AIM ImmunoTech Inc is trading 84% down today following heavy dilution from a $2.65M equity offering
AIM ImmunoTech Inc is trading 84% down at $0.45 following an extreme dilution-driven selloff tied to its latest capital raise. • The company announced a $2.65...
🔴 AIM ImmunoTech Inc is trading 5.5% down today extending losses after a massive dilution-driven selloff
AIM ImmunoTech Inc is trading 5.5% down at $0.38 in pre-market, continuing a sharp downward trend following an 85% plunge on June 9. • The selloff was...
🔴 AIM ImmunoTech Inc is trading 85.4% down today after $2.65M at-market financing announcement
AIM ImmunoTech Inc is trading 85.4% down at $0.40 after announcing a $2.65 million at-market financing on June 9, 2026. • The financing was priced at $0.5189...
AIM ImmunoTech Highlights Ampligen's Potential as an Ebola Virus Disease Therapeutic
AIM ImmunoTech Inc. released an investor video presentation and press release on June 4, 2026, detailing previously published pre-clinical data on its lead...
🔴 AIM ImmunoTech Inc is trading 11.4% down today as profit-taking continues after trial-driven surge
AIM ImmunoTech Inc is trading 11.4% down at $0.73 as the sharp pullback from last week’s trial-fueled spike continues. • The stock more than doubled recently...
🔴 AIM ImmunoTech Inc is trading 13.3% down today as profit-taking extends a pullback from its recent trial-driven surge
AIM ImmunoTech Inc is trading 13.3% down at $0.72 in pre-market, extending a sharp pullback from its recent speculative surge. • The stock more than doubled...
🔴 AIM ImmunoTech Inc is trading 7.2% down today as profit-taking continues after pancreatic cancer trial rally
AIM ImmunoTech Inc is trading at $0.77 (7.2% down) in after-hours trading as the stock enters a sharp giveback phase following a recent speculative surge. •...
AIM ImmunoTech Soars Then Stumbles on Pancreatic Cancer Trial News — Can a 20-Employee Biotech Survive the Road to Phase 3?
Shares of AIM ImmunoTech whipsawed this week, surging more than 120% on June 1 before pulling back 13.4% to $0.78 the next day, as traders locked in gains from...
🔴 AIM ImmunoTech Inc is trading 13.4% down today as shares pull back following a sharp rally on trial enrollment news
AIM ImmunoTech Inc is trading at $0.78 (13.4% down) as the stock experiences a pullback following a significant two-day surge tied to its pancreatic cancer...